Home / Drugs / elapegademase-lvlr

elapegademase-lvlr

FDA Drug Profile — Revcovi

Drug Details

Generic Name
elapegademase-lvlr
Brand Names
Revcovi
Application Number
BLA761092
Sponsor
Chiesi USA, Inc.
NDC Codes
1
Dosage Forms
INJECTION
Routes
INTRAMUSCULAR
Active Ingredients
ELAPEGADEMASE

Indications and Usage

1 INDICATIONS AND USAGE REVCOVI is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. REVCOVI is a recombinant adenosine deaminase indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. ( 1 )